Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study

Journal of Clinical Oncology

Volumn 30, Issue 22, 2012, Pages 2718-2724

  Bachelot, Thomas ^a   Bourgier, Céline ^b   Cropet, Claire ^a   Ray Coquard, Isabelle ^a   Ferrero, Jean Marc ^c   Freyer, Gilles ^d   Abadie Lacourtoisie, Sophie ^e   Eymard, Jean Christophe ^f   Debled, Marc ^g   Spaëth, Dominique ^h   Legouffe, Eric ⁱ   Allouache, Djelila ^j   El Kouri, Claude ^k   Pujade Lauraine, Eric ^l  

^a UNIVERSITÉ LYON 1   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e CENTRE PAUL PAPIN   (France)

^f INSTITUT JEAN GODINOT   (France)

^g INSTITUT BERGONIÉ   (France)

^h Centre d'Oncologie de Gentilly   (France)

ⁱ Clinique de Valdegour   (France)

^j Centre François Balcesse   (France)

^k Centre Catherine de Sienne   (France)

^l UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; TAMOXIFEN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART FAILURE; HORMONE RESISTANCE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; INFECTION; LEUKOCYTE COUNT; LUNG EMBOLISM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPHIL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN THROMBOSIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIROLIMUS; TAMOXIFEN;

EID: 84864558874     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.0708     Document Type: Article

References (27)

1. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758-3767, 2000
2. Dodwell D, Wardley A, Johnston S: Postmenopausal advanced breast cancer: Options for therapy after tamoxifen and aromatase inhibitors. Breast 15:584-594, 2006 (Pubitemid 44509773)
3. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109, 2003 (Pubitemid 46606358)
4. Chia S, Gradishar W, Mauriac L, et al: Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT. J Clin Oncol 26:1664-1670, 2008
5. Yue W, Fan P, Wang J, et al: Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 106:102-110, 2007 (Pubitemid 47362658)
6. Miller TW, Hennessy BT, Gonzalez-Angulo AM, et al: Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120:2406-2413, 2010
7. Santen RJ, Song RX, Zhang Z, et al: Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 95:155-165, 2005 (Pubitemid 41137306)
8. deGraffenried LA, Friedrichs WE, Russell DH, et al: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10:8059-8067, 2004 (Pubitemid 39587547)
9. Boulay A, Rudloff J, Ye J, et al: Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11:5319-5328, 2005 (Pubitemid 41003721)
10. Beeram M, Tan QT, Tekmal RR, et al: Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 18:1323-1328, 2007 (Pubitemid 47305004)
11. Ellard SL, Clemons M, Gelmon KA, et al: Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27:4536-4541, 2009
12. O'Donnell A, Faivre S, Burris HA III, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588-1595, 2008
13. Tabernero J, Rojo F, Calvo E, et al: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610, 2008
14. Awada A, Cardoso F, Fontaine C, et al: The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer 44:84-91, 2008 (Pubitemid 350256937)
15. Baselga J, Semiglazov V, van Dam P, et al: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630-2637, 2009
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000 (Pubitemid 30099779)
17. Common Terminology Criteria for Adverse Events version 3.0. http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ctcaev3. pdf
18. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
19. Thürlimann B, Robertson JF, Nabholtz JM, et al: Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39:2310-2317, 2003 (Pubitemid 37214855)
20. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al: Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987-1992, 2008
21. Johnston SR: New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 16:1979-1987, 2010
22. Treeck O, Wackwitz B, Haus U, et al: Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 102:292-299, 2006 (Pubitemid 44041641)
23. Chow LWC, Sun Y, Jassem J, et al: Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006
24. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520-529, 2012
25. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
26. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
27. Krueger DA, Care MM, Holland K, et al: Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801-1811, 2010